{
    "id": 31774,
    "fullName": "MAP2K4 L168F",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MAP2K4 L168F lies within the protein kinase domain of the Map2k4 protein (UniProt.org). L168F has been identified in the scientific literature (PMID: 29795445), but has not been biochemically characterized and therefore, its effect on Map2k4 protein function is unknown (PubMed, Dec 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6416,
        "geneSymbol": "MAP2K4",
        "terms": [
            "MAP2K4",
            "JNKK",
            "JNKK1",
            "MAPKK4",
            "MEK4",
            "MKK4",
            "PRKMK4",
            "SAPKK-1",
            "SAPKK1",
            "SEK1",
            "SERK1",
            "SKK1"
        ]
    },
    "variant": "L168F",
    "createDate": "12/12/2019",
    "updateDate": "12/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 185901,
        "transcript": "NM_003010",
        "gDna": "chr17:g.12095683C>T",
        "cDna": "c.502C>T",
        "protein": "p.L168F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19524,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model with pancreatic ductal adenocarcinoma harboring MAP2K4 L168F demonstrated reduced tumor volume when treated with Mektovi (binimetinib) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34166,
                "profileName": "MAP2K4 L168F"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34166,
            "profileName": "MAP2K4 L168F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 185901,
            "transcript": "NM_003010",
            "gDna": "chr17:g.12095683C>T",
            "cDna": "c.502C>T",
            "protein": "p.L168F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}